Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › AmoyDx Lung Cancer CDx Approved in South Korea

AmoyDx Lung Cancer CDx Approved in South Korea

Oct 12, 2018
|
staff reporter

NEW YORK (GenomeWeb) — Chinese diagnostics firm AmoyDx announced this month that South Korea's Ministry of Food and Drug Safety has approved its ROS1 fusion assay as a companion diagnostic for Pfizer's non-small cell lung cancer (NSCLC) drug Xalkori (crizotinib).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. BioReference Settles False Claims, Kickback Allegations for $11.5M

  2. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  3. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  4. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

  5. JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.